Patogênese e perspectivas de tratamento da Covid-19: uma revisão
DOI:
https://doi.org/10.33448/rsd-v9i7.3730Palavras-chave:
Patogênese; Tratamento farmacológico; Coronavírus.Resumo
Objetivo: apresentar a forma de ação e interação do SARS-CoV-2 com as células humanas e descrever os principais estudos sobre o tratamento para a Covid-19. Metodologia: foi realizada uma revisão nas bases de dados Science Direct-Elsevier e PubMed com análise de trabalhos experimentais in vitro e in vivo, de revisão, de notas técnicas e registros de pesquisas clínicas. Os termos utilizados foram: Coronavírus, COVID-19, SARS-CoV-2 associadas com pathogenesis, clinical studies e treatment. Resultados: Muitos estudos estão em desenvolvimento para entender a patogênese do vírus e buscar terapias eficientes para conter a COVID-19, como a cloroquina, hidroxicloroquina, Arbidol, favipiravir, remdesivir, entre outros. Conclusão: Este artigo revisou mecanismos de ação do SARS-CoV-2 a fim de fornecer informações para o melhor entendimento das ações adotadas por diversos pesquisadores na terapia contra a COVID-19. Muitos medicamentos estão em fases clínicas de experimentação para saber se podem minimizar os graves efeitos do vírus na população.
Referências
Casadevall, A., & Pirofski, L. (2020). The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation, 130 (4), 1545-1548.
Catella-Lawson, F. et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine, 345 (25), 1809-1817.
Chen, C.et al. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv, 3 (17), e20037432
Chen, J. (2020). Pathogenicity and transmissibility of SARS-CoV-2 quick overview and comparison with other emerging viruses. Microbes and Infection, 22 (2), 69-71.
Chen, N. et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395 (10223), 507-513.
Colson, P. et al. (2020). Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents, 5 (41), e105932.
Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14 (1), 58-60.
Elfiky, A. A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, 2020.
Fitzgerald, G. A. (2020). Misguided drug advice for COVID-19, Science, 367 (6485) e1434.
Fung, S.et al. (2020). A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defense: lessons from other pathogenic viruses. Emerging Microbes & Infections, 9 (1), 558-570.
Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends, 14 (1), 72-73.
Gautret, P. et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, e105949.
Han, Y., & Yang, H. (2020). The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID‐19): A Chinese perspective. Journal of Medical Virology, 1-6.
Hilgenfeld, R. (2014). From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design, The FEBS journal, 281 (18), 4085-4096.
Holshue, M. L. et al. (2020). First case of 2019 novel coronavirus in the United States. New England Journal of Medicine, 382 (10), 929-936.
Huang C. et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 15 (395), 497-506.
Khan, S. et al. (2020). The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. Journal of Clinical Microbiology.
Li, Q. et al. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine, 382 (13), 1199-1207.
Liu, C. et al. (2020). Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science, 6 (3), 315-331.
Liu, J. et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6 (1), 1-4.
Liu, J. et al. (2020). Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. Journal of Medical Virology, 92 (5), 491-494.
Lu, R. et al. (2020). Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 95 (10224), 565-574.
Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., & Cauda, R. (2003). Effects of chloroquine on viral infections: an old drug against today's diseases? The Lancet Infectious Diseases, 3 (11), 722-727.
Sheahan, T. P. et al. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 11 (1), 1-14.
Shereen, M. A. et al. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91-98.
Singh, A. K. et al. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14 (3), 241-246.
Wang, M. et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (SARS-CoV-2) in vitro. Cell research, 30 (3), 269-271.
Wang, W., Tang, J., & Wei, F. (2020). Updated understanding of the outbreak of 2019 novel coronavirus (SARS-CoV-2) in Wuhan, China. Journal of Medical Virology, 92 (4), 441-447.
Zhan, L. et al. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, eabb3405.
Zhang, W. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology, 214, e108393.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
